| Autor: |
Semenov AL; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Tyndyk ML; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Von JD; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Ermakova ED; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia.; Institute of Biomedical Systems and Biotechnology, Peter the Great St. Petersburg Polytechnic University, 195251 Saint Petersburg, Russia., Dorofeeva AA; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Tumanyan IA; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Radetskaya EA; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Yurova MN; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Zherebker A; Skolkovo Institute of Science and Technology, 121205 Moscow, Russia., Gorbunov AY; Research Institute of Hygiene, Occupational Pathology and Human Ecology, 188663 Saint Petersburg, Russia., Fedoros EI; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Panchenko AV; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia., Anisimov VN; N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia. |
| Abstrakt: |
Prostate cancer (PCa) is one of the most common male malignancies worldwide. In the current study, we evaluated the effects of a natural deep eutectic solvent (NADES) extract of Pueraria lobata roots rich in isoflavones (ISF) and Phaffia rhodozyma extract rich in astaxanthin (ASX) on an N -methyl- N -nitrosourea plus testosterone PCa model in rats. ISF consisted of puerarin, daidzein, genistein, formononetin and other polyphenols, while ASX contained lipids and unsaturated species in addition to astaxanthin. Extracts were administered through a whole promotion period in daily doses shown by our group to successfully inhibit benign prostate hyperplasia (BPH) development - 200 mg/kg for ISF and 25 mg/kg for ASX. Though a similar effect was found for BPH processes accompanying PCa induction, the incidence of PCa in animals treated with placebo, ISF and ASX was 37%, 37% and 41%, respectively, showing no chemopreventive activity of ISF and ASX. PCa development was associated with a decrease in the Ca/Mg ratio in serum and an increase in prostate tissue. Treatment with both extracts produced a normalization effect on Ca balance in serum, which, combined with a decrease in the prostatic index, suggests some positive health effects of ISF and ASX. |
